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Abstract A synopsis of the 2007 annual progress report
for the Center for Structures of Membrane Proteins, a
specialized center of the Protein Structure Initiative.
Keywords Membrane proteins  Structural biology 
X-ray crystallography  NMR, 2-D crystallography
Mission of the CSMP research center (csmp.ucsf.edu)
The goal of the Center for Structures of Membrane Proteins
(CSMP) is to express, purify and determine the structures
of representative members of membrane protein classes,
aiming for coverage of membrane proteins of novel folds,
and novel functions. Nearly 30% of all eukaryotic proteins
are membrane proteins, and these include protein targets
for over 40% of all drugs in use today. There is little
understanding of the mechanisms and atomic interactions
of any one of these. This is primarily because they are
membrane proteins, where preparation in a structurally
homogeneous and functionally active-state, and subsequent
structure determination has been extremely challenging.
Where classes of membrane proteins are represented in
prokaryotes, it is likely that structures for a homolog will
be determined first for prokaryotic or archaeal members, so
target proteins will be first sought from these organisms.
Our plan proposes structure determination of membrane
protein targets with two or more membrane crossings, from
prokaryotic, archaeal, extremeophile, and human genomes.
Many human proteins have no good homologs in pro-
karyotes or archaea, thus human membrane targets are also
included with the goal of coverage of the folds of the
membrane proteome. The human genes are the only ones
from a eukaryote, selected because their structures can
instruct in structure-based drug design.
Overall organization of the U54 research center
CSMP (csmp.ucsf.edu) supports an integrated program
aimed at facilitating the cloning, expression purification,
crystallization, and structure determination of membrane
proteins with the aim of coverage of the membrane pro-
teome. The core capabilities provide for fermentation, cell
culture, gene cloning, expression, protein purification,
characterization, X-ray diffraction at the Advanced Light
Source (ALS) in Berkeley, structure determination by 2-D
electron microscopy, and structure determination by
Nuclear Magnetic Resonance techniques (NMR).
The executive council consists of the seven principal
investigators. Delegated areas of responsibility include
responsibility over the projects. Dr. Sali directs the effort in
dynamic target selection, and also the final step in using
structures determined in the Center to model the structures
of homologs. Dr. Choe leads the effort to optimize
expression of human membrane proteins in E. coli using
the MISTIC system that he discovered. Dr. Stroud will
manage the standardized effort to express bacterial and
archeal membrane proteins in E. coli. Drs. Choe, Minor
and Stroud will oversee the purification and
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characterization of proteins produced in their projects. In
almost all cases, prokaryotic and human membrane protein
targets are investigated through the CSMP and all the other
eukaryotic membrane protein targets are investigated
through MPEC. However, the funding of the MPEC center
did not provide funds for crystallography or structure
determination equipment or personnel. Therefore, promis-
ing eukaryotic membrane protein targets that move through
the Stroud portion of the MPEC protein expression and
purification pipeline to a pure, homogeneous, and stable
preparation state are then incorporated into the CSMP
crystallography and structure determination pipeline.
The Principal Investigators derive from four institutions,
all located in California. The institutions are UCSF
(Stroud, Sali, Minor, and Holton), Salk Institute (Choe,
Riek, and Kwiatkowski), UCDavis (Stahlberg), and UCLA
(Kaback). The PIs and members of the team meet each
week in televised conference (1.00 pm–3.00 pm each
Tuesday) to present progress in rotation. After 1.5 years we
held a self-evaluation to identify weak projects and to plan
for any redirection of effort, and resources. Each aim will
now be gauged by 3-monthly milestones that will be used
to adjust direction and necessary funding. This will be
reviewed annually to assure direction.
The principal investigators
The investigators are in close touch with each other via an
intranet, phone, and direct contacts. The institutions are
UCSF (Stroud, Sali, Minor, and Holton), Salk Institute
(Choe, Riek, and Kwiatkowski), UCDavis (Stahlberg), and
UCLA (Kaback). Each principal investigator has played a
key role in the discovery of major membrane protein
biology, and/or in the development of procedures to
understand membrane proteins at the molecular level.
Robert Stroud and his group have studied many mem-
brane protein systems seeking characterizations and crystal
structures. So far they have determined 7 high-resolution
structures of membrane proteins at atomic resolution, one
to 1.35 A˚ resolution, currently the highest resolution of any
membrane protein structure. They also report the mecha-
nism of targeting membrane proteins to the endoplasmic
reticulum membrane by the signal recognition particle and
its receptor complex interaction.
Dr. Andrej Sali is a leader in development of methods
for protein structure analysis and prediction. He has played
a key role in the New York Structural Genomix Research
Consortium aimed at soluble proteins.
Senyon Choe’s group has elucidated mechanisms of
potassium channels from structure analysis of domains of
these channels. Dr. Choe has pioneered the MISTIC
method for production of membrane proteins from all
species, in E. coli.
Daniel Minor has also played a key role in under-
standing the regulation of potassium and calcium channels.
He determined key structures that help elucidate the
mechanisms of these channels. He has also developed
schemes to test for membrane stability.
Ronald Kaback is world renowned for his extensive
studies of the Lactose permease. Over many years he has
been a pioneer in membrane biology. Kaback recently was
coauthored with Iwata of the high-resolution structure
determination of the Lac permease. Thus his extensive
mutational analysis of Lac permease is legendary and can
now be interpreted.
Henning Stahlberg is a world leader in electron and
atomic force microscopy of membrane proteins. He beau-
tifully elaborated the structures of the GlpF and other
aquaporin channels in their membrane environment.
Dr. Roland Riek is an inventor of TROSY and an expert
in the use of NMR for three-dimensional structure deter-
mination focused on membrane proteins. He studied under
the tutelage of Dr. Kurt Wuthrich.
Dr. James Holton (a key person at the ALS) is one of
the world leaders in development of synchrotron and
storage ring sources for high throughput X-ray diffrac-
tion. He has made fundamental contributions to the
operations of beamline 8.3.1 that is currently the model
for others as they come on line at the ALS. He is a
highly innovative developer. For example he developed a
robotic mounting system for crystals at beamline 8.3.1 for
under $5,000.
Scientific progress
Progress in the development of new methods,
technology, approaches, and ideas for protein
production and structure determination
This PSI Specialized Center focuses on membrane pro-
teins. We target prokaryotic proteins expressed in
prokaryotic organisms as the most amenable system for
producing proper expression and targeting of these proteins
to the cellular membranes. We believe that these will
provide the most efficacious pathway to determining the
structures of new membrane protein folds and proteins. We
believe that archaebacterial and human membrane proteins
provide an intermediate pathway to provide new folds and
proteins since they may be evolutionarily intermediate
between prokaryotic and eukaryotic membrane proteins.
We also focus on human membrane proteins, while they
represent the most technically difficult class of targets; they
also have the highest potential value for structure based
drug design. Finally, we use all of our skills and technology
at our disposal to also target selected membrane protein
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complexes for expression and subsequent purification,
crystallization, and structure determination.
Molecular biology of selected targets
With over 700 E. coli targets to modify for the Ligation
Independent Cloning (LIC) method and test for proper
insertion of the target gene into the various expression
vectors, we were right on the border of being able to effi-
ciently using medium to high throughput molecular
biology as opposed to purely manual methods. Melissa Del
Rosario was instrumental in developing methods and
techniques for using vacuum manifold based techniques on
96 well plates. These techniques permitted the screening of
288 constructs/day and allowed the efficient incorporation
of our target genes into a variety of expression vectors.
Expression
The initial bottleneck for determining structure is mem-
brane protein expression. Expression in bacteria is being
carried out utilizing a novel scheme developed and applied
by Senyon Choe, termed MISTIC, and by standardized
procedures in E. coli that have already yielded high-reso-
lution membrane protein structures in the Stroud and
Kaback laboratories. We are also using codon optimization
to improve expression of non-native proteins in our
expression host cells, and Cell-Free Synthesis to target
proteins that resist in vivo expression methods.
Human membrane proteins that are not expressed
adequately or correctly folded by the above procedures
will also be expressed through the NIH Roadmap Center
directed by Stroud (GM-73210, Membrane Protein
Expression Center, MPEC) funded in October 2004. The
Membrane Protein Expression Center focuses specifically
on developing novel methods for expression of eukary-
otic (only) membrane proteins, and synergism with that
center is expected to leverage results with this Structural
Center.
Purification and characterization
Purification, solubilization and characterization are carried
out as core functions at UCSF. The Protein Analysis Core
at the Salk run by Kwiatkowski is developing High
Throughput SELDI mass spectroscopy for molecular mass
identification, NMR Analysis for detergent exchange, and
ultracentrifugation to determine quaternary structure. As
we approach the 4th year’s operation of CSMP, many
targets are emanating from the expression efforts and
entering the Purification and Characterization cores. In our
hands, automation of purification is still premature as an
option for membrane proteins primarily because of the
need for hand-tuned optimization of extraction, purification
stability, and solubility, in which each step involves
screening many different detergents. Thus, as our expres-
sion pipeline is becoming efficient, protein purification to a
pure homogeneous and stable form is the current bottle-
neck. We have addressed this bottleneck by setting up 5
HPLC stations, 2 Tetra Detector HPLC Analysis stations
and 5 single detector isocratic or gravity chromatography
stations several with auto-injectors and auto fraction
collectors.
Crystallization and structure determination
High throughput crystallization methods and trials are
being developed at UCSF. James Holton (UCSF and the
Advanced Light Source (ALS) in Berkeley) is addressing
bottlenecks in X-ray data collection and data analysis for
3D structure determination. Henning Stahlberg, UCDavis,
is developing methods for streamlining EM structure
determination, including automation of data collection and
sample preparation. Electron crystallography is also being
used to validate that the structures of 3-D crystalline
samples are congruent with those in the 2D bilayer. Some
membrane proteins may evade both structure determination
schemes. NMR will be applied in these cases by Roland
Riek for small size targets in addition to its own set of
targets from E. coli.
MISTIC homologs (Senyon Choe, Salk)
Mistic-based over-expression of bacterial kinase receptors
has provided a significant advantage of over-producing this
class of target proteins over other methods. But for mam-
malian integral membrane protein targets, it still needs
significant optimization. Apart from using Mistic for pro-
tein expression, we have also made efforts to understand
the function of the Mistic protein in the Bacillus organism.
We have focused on the role by up-regulating the expres-
sion of Mistic in Bacillus. It led to a surprising
consequence. It promotes the formation of biofilm and
endows antibiotic resistance in Bacillus. To some extent,
the same physiological results can be reproduced when E.
coli is transfected and up-regulated by Mistic expression.
Several Mistic homologs have been studied for their
structures. One such homolog we termed M2 behaves well,
and a 3.5 A˚ dataset has been obtained from M2 crystals.
The structure solution has not yet been obtained. Another
such homolog we termed M1 behaves well in solution, for
which high-quality NMR spectra have been obtained. Near
complete assignment of M1 spectral peaks has been
accomplished. These homologues have 62–93% residue
identity, and are all 84 residues in length, corresponding to
the three helices minus the first N-terminal helix of B.
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subtilis Mistic. In every case, these Mistic homologs have
an overlapping gene read-out with a downstream gene that
resembles a potassium channel protein. The functional
relationship between the two genes is unknown.
Mistic technology has a limited use for eukaryotic tar-
gets. In order to explore the possible use of Mistic for
eukaryotic targets, we have initiated using Mistic in lieu of
a signal sequence present at the N-terminus of typical
eukaryotic membrane protein genes. Initial expression
constructs have been designed and will be compared to a
comparable designer vector containing only the first alpha
helical domain in place of the entire Mistic sequence. Once
the designed vectors are available for tests, we will use the
human integral membrane protein library that consists of
*3,270 target genes that have been constructed as a
Gateway-adapted entry vectors.
In vitro expression (Robert Stroud)
Reconstituted cell-free (CF) protein expression systems
hold the promise of overcoming several of the traditional
barriers associated with in vivo systems. To evaluate the
potential of cell-free expression, we cloned 120 membrane
(\30 kDa) proteins from E. coli and compared their
expression profiles in both an E. coli in vivo system and an
E. coli derived cell-free system. Our results indicated that
cell-free was a robust system able to express 63% of the
targets compared to 44% in vivo (reported in Yr. 2).
However, when evaluating an expression system, many
factors, such as cost, complexity, throughput, reaction
efficiency and duration, personnel time, and protein qual-
ity, must be taken into account. While cell-free is a robust
expression system capable of expressing more proteins
than an in vivo system and suitable for production of
membrane proteins at the milligram level for a relatively
small cost when producing the S30 fraction in house; the in
vivo system is more streamlined, able to be scaled up much
easier with our equipment, and more economical in all
cases where expression is successful. We are investigating
the addition of lipids and/or detergents into the cell-free
reaction mixtures to investigate the potential to increase
expression and perhaps address the reaction duration
issues. If we select a high value target that is not amenable
to in vivo expression systems, we will try the cell free
approach, but even if the expression level in vivo is quite
low (\0.1 mg/l), our Sartorius fermentor units (2 9 15 l
and 1 9 75 l) can usually provide enough protein to per-
form useful experiments.
In year 3, we tested all of the phase 1 constructs that
were positive for in vivo expression in larger growth
volumes and prepared them for insertion into our regular
in vivo expression, purification, and crystallization
pathway.
Gene redesign and codon optimization (Robert Stroud
UCSF)
Expression of functional protein targets in heterologous
hosts is a key element of our efforts within the center.
Utilization of codon optimized synthetic genes has been
demonstrated in hundreds of published cases to increase,
often significantly, the levels of expressed material for
soluble proteins. Our efforts in CSMP focus on attempts to
translate this observation to expression of integral mem-
brane proteins. Within the past year we have generated
codon-optimized genes for 21 different proteins that have
lead to seven targets now in crystallization trials. Of these,
three have crystallized (Tacid1, SecY and PfAQP) and
have been optimized. Codon optimization for each of these
proteins was essential for expression success and moving
forward to crystallization trials. For instance, the native
PfAQP protein did not express, likely owing to the AT rich
character of the Plasmodium genome. Following optimi-
zation we are now obtaining *42 g of purified protein/liter
of culture. As evident from our initial expression results,
we generally observe an improvement in protein expres-
sion levels. PfAQP has now had its structure determined to
2.05 A˚ (PDB: 3C02).
The Stroud laboratory now has a collaboration with
DNA2.0 Inc. to pursue a study of the efficacy of codon-
optimized genes. Dr. Franklin Hays has provided DNA 2.0
with our hENT1 genes and with the collaboration of Dr.
Claus Gustafsson at DNA2.0, DNA2.0 will produce 20–25
different codon-optimized genes for CSMP to expression
test and prepare for eventual crystallization trials (Table 1).
LIC vectors (Daniel Minor, Robert Stroud)
In order to facilitate the large amount of cloning and
construct screening required for the efforts of the labs
involved in this PSI center, the Stroud and Minor labs have
developed a suite of expression vectors that implement
Ligation Independent Cloning (LIC) strategies. This
approach obviates the use of restriction enzymes for join-
ing target protein DNA to the vector and the need for
enzymatic ligation steps in clone preparation. The method
is efficient and yields *90–100% positive clones. We have
constructed LIC E. coli vectors bearing two N-terminal
affinity tags in series, His6 and maltose binding protein
(MBP), followed by a tobacco etch virus (TEV) protease
site (termed HMT). The His6- and MBP-tags allow for two
orthogonal affinity steps to be used in purification. The
TEV site permits specific cleavage of the tags following
purification. LIC cassettes with different combinations of
tags and utilizing the 3C (PreScission) protease have also
been constructed and used primarily by the Stroud
laboratory.
196 R. M. Stroud et al.
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Because CSMP focuses on the potential value of the
MISTIC fusion protein as a tool for expression of mem-
brane proteins in E. coli, we made LIC constructs (termed
HMisT) bearing, in series, His6, MISTIC, and the TEV
site. We have also generated HMT LIC and HMisT LIC
vectors that have an N-terminal signal peptide for use on
target proteins where the N-terminal domain is known to be
extracellular (ssHMT and ssHMisT).
Development of a rapid expression assay based on GFP
for proper expression and membrane insertion (Daniel
Minor)
In an effort to facilitate the screening and evaluation of
target proteins, we have developed an LIC expression
vector that uses green fluorescent protein (GFP) to monitor
target protein expression levels in E. coli directly. This
vector bears an LIC site followed by GFP and a His8
affinity tag. The premise is that only proteins that are
expressed and properly folded will give robust fluorescence
signals, as it is known that inclusion body formation sup-
presses the formation of the GFP chromaphore. Our initial
experiments confirmed that well-expressed proteins turn
the cells visibly green.
In the past year of effort we have used our GFP vector
format to screen the expression of 314 membrane proteins
from extremophilic organisms. We found that 67/314
(21%) of our extremeophile targets expressed as well or
better than the benchmark proteins in the GFP assay. To
investigate whether there was a correlation between GFP
fluorescence values (FSUs) and the amount of protein
produced in the membrane fraction, we took 36 targets (29
from the [60,000 FSU pool and seven from the \60,000
FSU pool) and subjected them to an expression optimiza-
tion protocol. We evaluated expression levels for each
construct (108 total) at three expression temperatures (18,
25, and 37C). 17 of our targets, once optimized, express at
[5 mg/l in the membrane fraction. Thus, the GFP screen
appears to be a reliable way to identify targets that have
good potential to express at high levels in the membrane.
Based on our results, there is a 90% probability that a target
with a fluorescence value[60,000 FSU can be expressed at
0.5 mg/l or better, levels that are sufficient for further
characterization and crystallization trials.
We pursued purification and characterization of 24 of
the targets that expressed at 0.5 mg/l or better. We are
actively pursuing purification optimization for each can-
didate as well as crystallization trials. Our plans for FY04
are to pursue crystallization and structure determination of
our cohort of well-expressed extremeophile membrane
proteins. Additionally, we plan to work with Dr. Greg Hura
at ALS beamline 12.3.1 to collect Small Angle X-ray
Scattering (SAXS) data on all well-behaved samples.
Recent implementation of robotic sample handling on the
Table 1 Progress table for the codon usage experiments
Gene Species Design Opt. For Status Native attempted Improvement
Tacid1 Thermus acidophilus DNA2.0 S. cer Crystals Yes *109
PfAQP P. falciparum Kosan E. coli PDB 3CO2 Yes *109
SecY Pyrococcus furiosus Kosan P. fur. Crystals Yes *49, essential
HPV-2B HPV Kosan E. coli Crystal trials No –
HPV-3A HPV Kosan E. coli Crystal trials No –
rGamma2 Rattus norvegicus DNA2.0 E. coli Crystal trials Yes *39
rGamma5 Rattus norvegicus DNA2.0 E. coli Crystal trials Yes *39
Tacid2 T. acidophilus DNA2.0 S. cer Purification Yes *109
Afmdr Archaeoglobus fulgidus DNA2.0 E. coli Purification Yes *29
hABCB1 Human Codon Devices S. cer Solubilization Yes *39
ha7 Human Kosan E. coli Solubilization No –
h3a Human Kosan E. coli Solubilization No –
hDAT Human Kosan E. coli Solubilization No –
hNET Human Kosan E. coli Solubilization No –
hSERT Human Kosan E. coli Solubilization No –
dSERT Human Kosan E. coli Solubilization No –
hABCA1 Human Codon Devices S. cer Expression Yes No, still blank on western
hRhAG Human GENEART S. cer Expression In progress No, slight decrease
hRhBG Human GENEART S. cer Expression In progress No
hRhCG Human GENEART S. cer Expression In progress Yes, detectable on western
C5aR Human Kosan S. cer Expression Yes Yes, detectable on western
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12.3.1 SAXS end station together with our cohort of well-
expressed, readily purified targets provides an excellent
opportunity to investigate the potential of a yet underuti-
lized way to obtain medium resolution information
(particularly regarding multimerization state) for mem-
brane proteins. It is anticipated that such efforts will also
aid in sample improvements for our efforts on structure
determination by crystallization and X-ray diffraction
methods.
Protein expression core (Witek Kwiatkowski, Casey
Johnson, Luis Esquivies, Christopher Dickson, Inno
Maslennikov, SALK)
We have standardized the steps of vector construction,
detergent screening, mini-scale expression tests, and protein
scale-up and subsequently trouble-shooting. Using these
standardized protocols, we plan to process 4 vectors made
per week, and 2 protein expression and scale-up per week,
on average. Once the expression vectors are made and
confirmed, mini-scale protein expression tests are per-
formed. Experiments to determine the optimal detergent
type, most effective solubilization time and detergent con-
centration will be performed and the data entered into
CSMP Central Database. Once the detergent is selected
from the screening and expression is confirmed, the
expression vectors are tested for scale-up protein prepara-
tion. As a general guideline, we evaluate by testing
detergent exchange and concentration by NMR, testing by
HPLC sizing, ion exchange chromatography, testing olig-
omeric state of the protein in solution by Analytical
Ultracentrifuge, choosing purification protocol, setting up
crystallization screens. If necessary, we change detergent
(decyl-D-maltopyranoside (DM), dodecyl-D-maltopyrano-
side (DDM), octyl l-D-glucopyranoside (OG), nonyl-D-
glucopyranoside (NG) are the choices) and repeat. This is
performed by the Protein Analysis Core. A typical target
protein will take 7 working days to pass through the
detergent screening with day one and two being used to
solubilize membrane preparations prepared before-hand,
days 3 and 7 to run the samples on size exclusion chro-
matography and run signature SDS–PAGE gels and western
blots and change and test different buffer conditions. Most
of this work is not particularly suited to automation except
through the use of auto-injectors on the HPLC systems.
Purification and characterization: high throughput
characterization of membrane protein detergent
complex (Kwiatkowski, SALK)
The identification and characterization of integral mem-
brane proteins (IMPs) require stable protein-detergent
complexes (PDCs) to be formed. We used a combination of
light scattering, refractive index measurement, mass spec-
troscopy, NMR spectroscopy, and ultracentrifugation to
carefully characterize detergents and proteins and their
relative compositions in the PDCs. This information was
essential to evaluate oligomeric states of samples, and thus
the feasibility of crystallization.
We use 1D-NMR spectroscopy to quantitatively monitor
detergent concentration during sample purification. These
data provide a useful gauge of the detergent’s extraction
potential for a given protein, detergent exchange efficiency,
and detergent concentration after final ultra-filtration. To
assess the homogeneity and oligomeric state of PDCs we
used HPLC in line with light scattering, UV and refractive
index instruments or, alternatively, the sedimentation
velocity measurement by analytical centrifugation. These
methods provide us with the quantified detergent-to-protein
ratio and the mass of the entire PDC, and thus with the
precise PDC composition. They also allow us to assess the
capability of detergent additives to influence these impor-
tant parameters.
Crystallization and structure determination: automation
of crystallization trials (Robert Stroud)
In the process of 3D structure determination of biological
macromolecules, crystallization constitutes one of the
major bottlenecks. The scarcity of sample for crystal trials
constitutes a limiting step in particular in the case of
membrane proteins. At the CSMP, we have implemented a
‘high-throughput’ crystallization strategy that covers two
aspects: Robotic screening and optimization of crystalli-
zation conditions. A nanoliter scale crystallization robot
(Mosquito from TTP LabTech) is used to perform crys-
tallization trials in 96 well-format plates. It is designed to
prepare drops in both hanging- or sitting-drop mode using
the vapor diffusion method. Drop size can be reduced to
200 nl (100 nl ? 100 nl) without loss of accuracy and
efficiency. This robot is easy to use, and it is a positive
displacement pipetting robot that uses disposable tips. It
therefore eliminates the risk of cross-contamination, and it
eliminates the need for cleaning the tips.
This system is used for screening initial crystallization
conditions and also for optimization using a set of additive
screens. We keep approximately 20 commercial crystalli-
zation screens of 96 conditions on-hand giving researchers
1,920 unique crystallization conditions in addition to cus-
tom chemical components. Working with 100 nl of a
protein solution and 100 nl of the crystallization screen
requires \10 ll of protein solution instead of the 192 ll
needed for manual drop setting methods (2 ll ? 2 ll
drops). This represents a 209 reduction in the protein
needed for each screen and thus a 209 increase in the
number of screens that we can perform with a given
198 R. M. Stroud et al.
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volume of protein preparation. This improvement in effi-
ciency permits effective screening with proteins that
express 209 less that before, putting our minimum useful
expression level around 0.1 mg/l. This crystallization robot
was purchased by CSMP, and is shared, (as are costs) by all
members of CSMP, and also by the Macromolecular
Structure Group (msg.ucsf.edu), the Gladstone Research
Institute, and the QB3 Institute. About 20 different groups
currently use this robot.
Optimizing X-ray structure determination (James
Holton, Robert Stroud, ALS/UCSF)
Work continues on narrowing the large numerical gap
between collected data sets and published structures. World
wide, this gap is roughly 50 to 1, and our analysis of the
problem has demonstrated that this gap is due to a lack of
understanding of the data quality requirements of modern
structure-solving algorithms. Clearly, it is always best to
have high quality data, but optimizing throughput, effi-
ciency and success rates requires that the minimum data
quality requirements be known.
Establishing these limits empirically would require
collecting data sets from a wide range of proteins and
systematically varying different parameters such as crystal
size, mosaic spread, exposure time and others. This is a
very large parameter space. To aid this search, a quanti-
tative model of the diffraction experiment and all its
various sources of error was constructed. This diffraction
experiment simulator (MLFSOM) is now a mature system
and has begun to produce exciting results. Nearly all
important physical phenomena in the diffraction experi-
ment, including radiation damage, spot shape, anomalous
differences, diffuse scattering, shutter jitter and beam
flicker are all modeled from first principles. The simulation
is performed on an absolute scale, so once the correct real-
world values of flux, crystal volume and other physical
parameters are entered the simulated images are not only
remarkably realistic, but on the same scale as measured
diffraction patterns. The simulated images are output in the
.SMV file format so they can then be processed with
modern data-processing software. In this way, the effect of
varying experimental parameters (such as exposure time in
seconds or crystal size in microns) can be precisely cor-
related to data quality and the ‘‘threshold of solvability’’
established for each. The advantage of absolute scale is that
the optimal parameters derived from the simulation have
the same units as the optimal parameters for data collec-
tion. For example, it has been found that the read-out noise
of a modern detector has almost no impact on the accuracy
of anomalous difference measurements, which implies that
MAD/SAD data sets can be divided over many more
images than previously thought. This prediction was
experimentally tested, and it was found that higher
redundancy with the same total exposure actually improves
overall data quality. This new data collection strategy is
now strongly encouraged at ALS 8.3.1.
In May 2007, the ADSC Q210 detector in ALS 8.3.1
was replaced with a new, larger, ADSC Q315r detector.
The increased surface area and lower intrinsic noise have
enabled larger unit cell work, improved signal-to-noise
(longer detector distances) and a 10-fold increase in the
allowable data redundancy over the old detector. It is now
clear from our studies [1] and others that radiation damage
is fundamentally unpredictable. We have shown that heavy
atom sites decay exponentially with dose, and the decay
constants are reproducible for a given sample type. We
have established that the best strategy for MAD data col-
lection is to begin with a complete data set of very short
exposures (1 s or less) and then repeat the complete data
set with 29 the exposure time, then 49 the exposure time
and continue until the crystal shows signs of decay. This
decay can either be evaluated by monitoring the XANES
spectrum of the metal [1] or by visual inspection of the
decaying diffraction pattern. If the sites are robust, then all
the data sets can be merged together, and if the sites are
found to decay rapidly, then the radiation induced phasing
(RIP) technique can be applied between the first and last
data sets. Thus the same set of data is applicable to several
structure solution pathways.
Of course, once the requirements of a crystal are known,
one must find a crystal that meets them. Two novel
screening technologies are in development at ALS 8.3.1: the
Offline Target Indication System (OTIS) and the ‘‘plate
goniometer’’. OTIS circumvents the crystal-centering
problem by using optical microscope images of a hand-
centered crystal to re-center it at a later time. This effec-
tively enables unattended data collection, which is done late
at night. Screening is then done during the daylight hours,
when users are more alert. Delayed data collection has now
become a popular feature for users with overnight shifts.
The ‘‘plate goniometer’’ is an in situ screening system
developed in collaboration with the SIBYLS beamline
12.3.1 and Fluidigm Corporation. It is now operational and
screening crystals at a rate of one per minute. With this
system, crystals can be probed in their growth chamber,
which eliminates the caveats and the labor of harvesting,
mounting and cryoprotecting each crystal, all important
considerations in crystal optimization. We have recently
begun applying this technology to novel structural projects,
including a membrane protein from CSMP.
Describe plans for FY04 research activities
The initial goals and principal persons proposed continue
along the lines of their initial goals. We need to make a
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more seamless transfer of membrane proteins to electron
microscopic analysis, which is underutilized due to supply
at present. As new proteins are now being produced the
equation has evolved and demands this streamlined transfer
of material to UC Davis.
Bioinformatic methods will be applied increasingly here
to help in pinpointing structures of highest impact on the
membrane proteome. Increased focus will be added to the
human membrane protein genes being assembled in
GATEWAY vectors by Dr. Choe. These will be expressed
as MISTIC fusions at CSMP.
We have set-up a multi-center crystallization method
comparison with several PSI centers (Hauptman–Wood-
ward Institute, Ismagilov Laboratory at the University of
Chicago, and the Kenis Laboratory at the University of
Illinois Champaign-Urbana, Fluidigm Corporation) that
specialize in high throughput crystallization methods. We
will be able to assess the success of each method via their
results with a standardized protein preparation that we
provide. CSMP is producing sufficient DjkA protein in a
PHS state to provide all of these groups with enough
protein to run a selected number of our favorite commercial
crystallization screens.
At the end of year 3, the Stroud laboratory has 735
prokaryotic membranes cloned, 240 proteins demonstrating
significant expression, 85 that have been solubilized, 36 in
membrane purification; 11 entered crystallization, 11
crystallized, 6 diffracted and have 3 structures. We can
expect a dramatic ramp up as we enter more proteins into
purification.
All the CSMP centers combined have 1072 proteins
listed on our website database CSMP Central. To date, 771
have been cloned, 564 have tested positive for useful
expression, 62 have been solubilized, 38 were PHS, 13
produced crystals, 11 diffracted, and 11 structures were
determined.
Progress on production and structural determination of
non-redundant proteins from classes of challenging
proteins: introduction and background
Many eukaryotic membrane protein families have close
homologs in bacteria whose structures provide insight
into the structures of eukaryotic family members.
Therefore a major focus is to determine the structures of
E. coli membrane proteins. E. coli however, does not
contain representatives of many families found in mam-
mals, hence the focus on archaea and human membrane
proteins. The major subclass in human is those mem-
brane proteins that are localized in functional form in the
plasma membrane of the cell. These include many drug
targets.
Describe your plans and progress in selecting targets for
production and structure determination and structural
coverage at granularity consistent with the PSI-2
policies and appropriate for your class of challenging
proteins
Target selection
Objective: Develop a target selection strategy to sample a
broad range of membrane proteins from set of selected
prokaryotic and eukaryotic organisms.
Targets of special interest
(a) Extensive pipeline of E. coli and prokaryotic membrane
proteome proteins (Stroud), (b) Membrane Protein Com-
plexes from Prokaryotes (Stroud), (c) E. coli membrane
proteins expressed from the in vitro/in vivo comparison
(Stroud), (d) ABC and SLC transporters (Giacomini), (e)
Bacterial receptor kinases (Choe), (f) Lactate symporter
and H?/nucleobase-ascorbate symporter YgfO (Kaback),
(g) Transporters and channels (Stroud). Ammonia chan-
nels, Mercury transporters, aquaporins (Stroud), and (h)
extremeophile membrane proteins (Minor).
Target selection (Andrej Sali, UCSF)
As part of the CSMP effort, we selected a set of target
proteins for structural studies that maximizes coverage of
integral a-helical membrane proteins in the S. cerevisiae
while at the same time minimizing the number of
sequences.
We used our analysis to guide target selection for the
structural genomics of membrane proteins in yeast, aiming
for complete coverage of integral membrane proteins pre-
dicted to have three or more alpha helices. We found that
complete profile-based sequence coverage of the yeast
genome required 361 total targets of the 622 total.
The overall membrane protein annotation process con-
sisted of the following five steps detailed in Fig. 1:
Membrane protein annotation pipeline. First, we identified
integral membrane protein families in the Pfam database of
protein families. Second, we collected protein sequences
encoded by a diverse set of 34 genomes of interest to
CSMP and predicted a-helical transmembrane proteins.
Third, we generated sequence profiles for the identified
membrane proteins in each genome and annotated the
sequences in each sequence profile with organism and
protein family identifiers. Fourth, we enumerated mem-
brane protein families in each genome and connected
significantly related membrane proteins both within
organisms and across organisms. Finally, we constructed
comparative protein structure models for all known
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sequences from Uniprot based on known atomic structures
of membrane proteins.
Complete profile-based sequence coverage of the yeast
genome therefore requires 361 total targets of the 622 total.
These sequences were added to the target selection tool and
entered in to the experimental structural characterization
pipeline in the Stroud group.
One goal of structural genomics is to improve compar-
ative modeling of sequence space. Finding homologs that
can be modeled based on a template structure is the first
step in the modeling process. We use our sequence profiles
for each target sequence as a proxy for how many
sequences could be modeled if we had a structure of the
target. In total, there are 415,983 sequences in Uniprot that
are detectably homologous to one or more of the CSMP
targets. We find that our target selection methodology
yields more unique modelable sequences and better profile-
based sequence coverage than randomly selected sequen-
ces at 30% sequence identity.
Focus on human ABC and SLC transporter homologs in
yeast
Two selected targets, the yeast genes STE6 and YN_99,
code for ABC transporters that are homologous to human
multidrug transporters in the B and G families, respec-
tively. There are 48 characterized ABC transporters in
the human genome and 18 are disease-associated.
Additional structural data these transporter families will
be invaluable for interpreting the results of functional
studies and suggesting mechanisms for clinical
phenotypes.
Expression of membrane proteins
Extensive pipeline of E. coli and prokaryotic membrane
proteome proteins (Robert Stroud). In the Stroud labora-
tory, we have a three phase organization to our work. First,
we initially started on a 120 protein project investigating in
vitro translation/expression. The results of this work were
published in 2007 and the target proteins that expressed
successfully moved into the purification pathway, this work
is continuing. The second phase was our ‘‘408’’ protein
project that was headed by Melissa Del Rosario. The pro-
teins in this project were selected with the aid of the
bioinformatics group in the Andrei Sali laboratory to pro-
vide extensive coverage of the Pfam classes in E. coli.
Phase 2 has provided a large number of proteins that are
ready for expression and solubility testing. From prior
experience it was decided to test for solubility in octyl
glucopyranoside (OG) detergent only. With this opera-
tional filter, we still had enough proteins that solubilized in
OG to saturate our purification resources. In Phase three,
since we had covered a significant part of the E. coli
genome already in the first two phases, it was decided to
complete the entire E. coli membrane protein proteome by
selecting the remaining unselected proteins. All three
phases are continuing presently.
Fig. 1 Bioinformatic flow chart
for CSMP protein target
selection
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E. coli membrane proteins expressed from the in vitro/
in vivo comparison (Robert Stroud)
Of the 120 proteins that were subject to expression testing
in both the E. coli, and by E. coli cell-free methods, 12 of
the membrane proteins [2] expressed at greater than one
milligram per liter of culture and were able to be solubi-
lized in OG and were therefore selected as targets for X-ray
crystallography. Four have gone forward to crystal trials,
and have been crystallized. CcmG and YijD crystals have
gone to the ALS and diffract to 2.3 and 7.5 A˚, respectively.
The structure of CcmG is currently being solved by
molecular replacement (a structure of the soluble compo-
nent of CcmG has been published, but not the
transmembrane segment). Crystals of YijD are being fur-
ther optimized with grid and additive screens.
Protein production and structure determination
(UCSF-Harries, Miercke, Stroud)
Prokaryotic membrane proteins
We currently have 735 prokaryotic membrane proteins in
our protein purification pipeline. So far, 155 proteins
express at levels high enough to proceed to solubility
testing using a detergent screen with six different deter-
gents representing three detergent chemical families. 85 of
the solubilized proteins have been successfully purified on
Ni IMAC. Once the Ni immobilized metal affinity chro-
matography (IMAC) purification efficiency has been
assured by SDS–PAGE and western blots, the histidine tags
are cleaved for preparative SEC runs. If the SEC produces
a pure homogenous single peak, the sample is tested for
stability; at this time, 34 of the post-SEC proteins are pure,
homogenous, and stable (PHS). If a protein preparation can
not be adequately purified by SEC, ion-exchange
chromatography using methyl sulphonate (S) or quaternary
ammonium (Q) matrices are used for further purification.
Size exclusion chromatography is routinely employed to
test the PHS condition of all preparations. Once a protein
preparation is PHS it is ready for crystal trials. At the end
of year 3, the Stroud laboratory has 735 prokaryotic
membranes cloned, 240 proteins demonstrating significant
expression, 55 that have been solubilized, 36 in membrane
purification; 11 entered crystallization, 11 crystallized, six
diffracted and have four structures. One structure is of a
primitive Rh factor from Nitrosomonas (PDB: 3bhs, [3]),
two are published structures of AQPM solved at 1.67 A˚
and 2.3 A˚ (PDB: 2evu and 2f2b, [4]), and the other is an
AmtB-GlnK complex refined to 1.95 A˚ (PDB: 2ns1, [3])
(Table 2). We can expect a dramatic ramp up as we enter
more proteins into purification. However, the bottleneck
for us is protein purification. We therefore seek to augment
the effort there with increased efficiency, additional chro-
matography stations, and possibly additional personnel if
we can appropriately refocus less productive prototype
experiments.
All the CSMP centers combined have 1072 proteins
listed on our website database CSMP Central. To date, 771
have been cloned, 564 have tested positive for useful
expression, 62 have been solubilized, 38 were PHS, 13
produced crystals, 11 diffracted, and 11 structures were
determined (Table 3).
Human membrane proteins
Thirty-six human membrane protein targets have entered
the Protein Expression and Production Pipeline. Ten of
these express adequately to continue through the pipeline.
So far, nine of these have been solubilized and moved on to
the purification process. Purification protocols for all 9 are
in the process of being fine-tuned. One human protein has
been crystallized.
Table 2 STROUD prokaryotic
membrane protein progress
Progress step Step description No. in group Total no. through this level
12 Structure 5 5
11 Diffraction 2 8
10 Crystals 0 8
9 PHS 25 33
8 S-Chrom 0 33
7 Q-Chrom 0 33
6 Tag Cleaved 0 33
5 SEC 2 35
4 Aff Chrom 0 35
3 Soluble 22 55
2 Significant exp 240 240
1 Selection 735 735
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Membrane protein complexes from prokaryotes (Robert
Stroud)
We have initiated collaboration with David Eisenberg’s
group at UCLA. He searched the four bacterial genomes to
identify genes encoding putative protein-protein complexes
where one member is a predicted to be a membrane pro-
tein. We obtained a total of 42 membrane protein-
containing complexes (86 proteins) from Acinetobacter
baylyi ADP1, Escherichia coli K12, Mycobacterium
tuberculosis H37RV, and Pseudomonas aeruginosa PAO1,
were chosen as targets for CSMP. All have two subunits
with the exception of one complex from E. coli, which has
four protein components.
Our aim is to co-express members of each complex in
the same E. coli cell host since co-expression may allow
association during synthesis, and bring advantages of sol-
ubility, activity and stability compared to proteins
expressed separately. We initially attempted an LIC Duet
cloning strategy marketed by Novagen; however this
method has been successful for only one complex.
We have cloned the all of the genes on separate com-
patible plasmids that can be co-transformed. Expression
testing is now ongoing.
Membrane transporters (Kathy Giacomini)
Membrane transporters play a critical role in drug dispo-
sition and response. The Pharmacogenomics of Membrane
Transporters project (PMT) is focused on discovering and
functionally evaluating genetic polymorphisms in 50
membrane transporters in the human genome. These
transporters are in two major super families, ATP Binding
Cassette (ABC) Superfamily and Solute Carrier Super-
family (SLC). The goal of our studies in the CSMP project
is to develop expression constructs of human membrane
transporters in appropriate expression vectors and func-
tional assays so that the transporters can be expressed in
abundance to facilitate the determination of structures. Our
laboratory clones the transporters from human and mam-
malian tissues and functionally characterizes the
transporters in mammalian expression systems. To date, 20
transporters have been cloned and functional assays
performed.
The goal of our studies in the CSMP is to develop
expression and purification protocols of functional human
membrane transporters for downstream structure determi-
nation and characterization. Another goal for the coming
year is to develop a collaboration with Volker Dotsch in the
expression and purification of membrane transporters in the
Solute Carrier Superfamily (SLC). Volker has developed a
non-cellular system of expression of large quantities of
membrane proteins.
Table 4 below describes progress made in our project
over the first 3 years.
Bacterial receptor kinases (SALK-Choe, Kefala)—
bacterial histidine kinase receptors (SALK-Choe,
Kefala)
Crystal structures of bacterial histidine kinase receptors are
the main targets of our efforts. To facilitate the structure
determination, we have carried out a systematic approach
in selecting and constructing expression vectors of these
family members. Based on the complete analysis of E. coli
genome, we identified 25 such E. coli’s kinase receptors,
23 of which are histidine kinase receptors and the
remaining two being tyrosine kinase receptors. All these
receptors are part of two-component transmembrane sig-
naling systems.
We have prepared a two-prong approach in making
expression constructs in order to analyze the
Table 3 CSMP membrane
protein progress
Progress step Step description No. in group Total no. through this level
12 Structure 11 11
11 Diffraction 11 11
10 Crystals 2 13
9 PHS 25 38
8 S-Chrom 0 38
7 Q-Chrom 0 38
6 Tag Cleaved 0 38
5 SEC 2 40
4 Aff Chrom 0 40
3 Soluble 22 62
2 Initial exp 628 628
1 Selection 1072 1072
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effectiveness of Mistic fusion on protein expression. Our
laboratory uses Gateway expression vector technology to
construct these vectors so it is very easy of put these
vectors together. One is fused with Mistic (Misticated),
and the other without Mistic (non-Misticated). Both carry
an octahistidine tag as an affinity tag to facilitate puri-
fication. These are further expanded by removing the
putative signal sequence present in the gene, also by the
addition of response regulators. This combinatorial mix
of about 100 protein constructs are at various stages of
the pipeline for overproduction. About 12 of those have
reached the stage of well-behaving protein (grade A)
purified at sufficient quantity for further work. The
crystallization efforts are being made with various
combinations of additives and detergents. The project
utilizes significantly a high-throughput crystallization
using Honeybee 96 robot in the laboratory. For human
targets, we continue to optimize the high-throughput
tools and vectors as well as control vectors to benchmark
the progress in order to process 35 plates currently in
possession, each containing 96 human targets. Lately, we
have initiated a new approach using Mistic as a signal
sequence of yeast expression system. All these expres-
sion vector systems rely on the Gateway technology to
ease the exchange of expression vectors for a target
gene.
Bacterial secondary transporters (UCLA—Kaback):
Nucleobase Cation Symporter 2 (NCS2) family
The H?/nucleobase-ascorbate symporter YgfO, which
belongs to the NCS2 family of transport proteins, is ubiq-
uitously found in all cells from archaea to eukaryotes. This
highly conserved family consists of purine, pyrimidine and
L-ascorbate transporters, with members specific for the
cellular uptake of uracil, xanthine or uric acid (microbial
and plant genomes) or vitamin C (mammalian genomes), as
well as several important purine-related drugs (5-fluoro-
uracil, allopurinol, oxypurinol). Thus, a crystal structure of
YgfO would be relevant to the development of anti-cancer
drugs, drugs to treat gout and anti- oxidants. We cloned
four members of NCS2 family from E. coli, T. thermo-
philus, P. furiosus as well as T. maritimus, and expressed
them in E. coli DE3 strain. Well-expressed YgfO from E.
coli and T. thermophilus are solubilized with Fos-choline
(FC)-14, purified by IMAC (Talon resin), yielding 1–2 mg/
l culture. Both proteins are stable on ice for at least 2–
4 weeks. Recently, initial crystallization screening by mi-
crobatch and hanging drop vapor diffusion yielded a few
‘hits’ for YgfO purified from E. coli HRK43. After brief
optimization, relatively large crystals (50 9 200 lm) were
obtained from salt-based crystallization conditions and
xanthine (Fig. 2).
Table 4 Progress of transporter cloning and functional characterization in the Giacomini Laboratory
Transporter MW Functional clone Yeast expression Solubilized Purified
1 hMATE1 61919 X *0.8 mg/l No No
2 rMATE1 61436 X *0.5 mg/l Yes No
3 hENT1 50216 X *2 mg/l Yes Yes
4 hENT2 50110 X *1.2 mg/l *50% Yes
5 hENT3 51712 X *0.8 mg/l *60% No
6 hCNT1 71580 X *1.0 mg/l Yes Yes
7 hCNT2 71991 X POOR Yes Yes
8 hCNT3 76925 X *0.5 mg/l Yes No
9 hOCTN1 62151 X *1.0 mg/l *50% No
10 hOCT1 61150 X *1.0 mg/l Yes No
11 hOCT2 62560 X *0.8 mg/l Yes No
12 hOCT3 61276 X *0.5 mg/l *60% No
13 hABCG2 72309 X 1.0 mg/l No No
14 hMATE2 – X Not tested Not tested Not tested
15 hOAT1 61812 X Not tested Not tested Not tested
16 hOAT2 59807 X Not tested Not tested Not tested
17 hOAT3 59853 X Not tested Not tested Not tested
18 hOAT4 62166 X Not tested Not tested Not tested
19 hOCTN2 62747 X Not tested Not tested Not tested
20 CTR1 – X Not tested Not tested Not tested
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The ion transporter superfamily (ITS)
Lactate permease (LctP) belongs to the ITS family found in
Gram-negative and Gram-positive bacteria, as well as Ar-
chaea. All LctP members are proposed to have 14–16
transmembrane -helices with both N- and C-terminal
exposed to the periplasm. We used the PhoA fusion
approach where the expression construct is made with an
embedded alkaline phosphatase sequence, permitting the
gene expression to be easily monitored by a simple alkaline
phosphatase assay. LctP appears to contain 14 transmem-
brane domains. E. coli LctP transports both L- and D-lactate
and is a lactate/H? symporter. It is also highly interesting
that LctP is one of a group of acidic substrates that seems
to be coupled to the pH gradient (interior alkaline) at
ambient acidic pH values, but coupled to the membrane
potential (interior negative) at more alkaline pH values.
Recently, it was reported that LctP from Neisseria gonor-
rhea is important for pathogenesis. Crystals of LctP were
obtained with PEG400/(NH4)2SO4 (pH 8.6) after several
months incubation. At the ALS beamline 8.2.1, anisotropic
diffraction is observed to 3.2/6.0 A˚ and a data set was
completed to 7.0 A˚.
Topology of MISTIC
MISTIC is a protein from Bacillus subtilis that is reported
to facilitate expression of eukaryotic membrane proteins in
E. coli. We have utilized the alkaline phosphatase (phoA)
fusion approach to study the topology of MISTIC in the
membrane of E. coli. The following PhoA fusions have
been constructed: MISTIC-K28, -Y58, P63, Q66, K86,
G115 and T139. The letters and numbers refer to positions
in MISTIC where PhoA (alkaline phosphatase) fusions
were constructed. For example, K28 means that the fusion
construct is MISTIC from position 1 to 28, and the rest of
the fusion protein is alkaline phosphatase. In order to be
active alkaline phosphatase must be translocated into the
periplasm. Since none of the fusions that Lan Guan con-
structed—which run the length of MISTIC—have alkaline
phosphatase activity, the observations would be interpreted
to mean that MISTIC has no transmembrane domains.
Incidentally, this is a technique that was developed origi-
nally by Manoil and Beckwith in the early 090s, and it has
been used to test the hydropathy models of many polytopic
membrane proteins in addition to LacY.
Transporters and channels (Stroud)
Ammonia channels
Inhibitory complex of the transmembrane ammonia chan-
nel, AmtB, and the cytosolic regulatory protein, GlnK, at
1.96 A˚ [3].
Ammonia conductance is highly regulated. A PII signal
transduction protein GlnK is the final regulator of trans-
membrane ammonia conductance by the ammonia channel
AmtB in E. coli. The complex formed between AmtB and
inhibitory GlnK at 1.96 A˚ resolution shows that the trimeric
channel is blocked directly by GlnK, and how in response to
intracellular nitrogen status, the ability of GlnK to block the
channel is regulated by uridylylation/deuridylylation at
Y51. ATP and Mg2? augment the interaction of GlnK. The
hydrolyzed product, adenosine 50-diphosphate (ADP) ori-
ents the surface of GlnK for AmtB blockade. 2-oxoglutarate
diminishes AmtB/GlnK association and plausible sites for
2-oxoglutarate binding were identified.
Fig. 2 a Photomicrograph of
crystals for YgfO obtained from
salt-based crystallization
conditions and xanthine.
b Photograph of a silver stained
SDS-PAGE gel showing the
protein composition of the
crystals harvested from the salt-
based crystallization conditions
and xanthine
2007 Annual progress report synopsis of the Center for Structures of Membrane Proteins 205
123
Rh Sub-family of Ammonia Channels: Rh50 of Nitroso-
nomas europea. (Stroud) Nitrosonomas europaea is an
obligate lithoautotrophic ammonia-oxidizing gram-negative
bacterium. NeRh is similar to evolutionary precursors of the
Rh family found in eukaryotes. It is 38% identical and has
strong similarity to human Rh factors. It has been demon-
strated to conduct ammonia without pH dependence seen in
the human Rh channels and the mechanism is remarkably
conserved to that of the Amt subfamily. Gas conduction is
not yet demonstrated in our functional testing. Unlike many
Rh ammonia channels, NeRh is not glycosylated. It is a tri-
mer of 42 kDa monomers. NeRh has been expressed in E.
coli obtained in pure, homogeneous and stable form. Robotic
crystal trials and optimization has yielded crystals that dif-
fracted to 2.0 A˚ and the structure solved by molecular
replacement. The refinement is complete for this structure
and is a significantly better model for the structure and
functional mechanism of the human channels.
The Kell/KX complex is responsible for the second most
common erythrocyte antigenic phenotype and we have
initial over-expression in S. cerevisiae.
Human RhCG has also been successfully expressed in
the membrane fraction of S. cerevisiae and HEK293 cells,
and it is soluble in OG and DDM.
Mercury transporters (Stroud)
In order to survive in mercury-rich environments, bacterial
mercury resistance operons utilize mercury transporting
membrane proteins, specifically MerT and MerC. In these
Mer systems the toxic mercury ion, Hg?2, is imported
through these transporters into the cell, where it is then
reduced from Hg?2 to Hg, a relatively inert elemental form
of mercury. These proteins are mechanistically interesting,
and they represent a novel structural family.
Two bacterial mercury transporters, MerT and MerC,
have been successfully cloned from Shigella flexneri into
bacterial over-expression plasmid vectors as His-affinity
tagged fusion proteins. Upon induction of expression in E.
coli, both MerT and MerC are highly over-expressed and
localized to the cell membrane, yielding approximately
4 mg of protein per liter of culture. We are near to final-
izing this purification protocol and scaling up efforts to
product quantities of MerT of suitable purity and low-
detergent concentration for crystallization screening.
Aquaporins (Stroud)
Aquaporins that also function in H2S transport are found in
archaea. One structure has been solved for methanobacter
AQPM, to 1.65 A˚. A second for A. fulgidus has been
crystallized. The glycerol channel from the malaria parasite
PfAQP has been subjected to gene design and synthesis,
and has been crystallized with diffraction to 2.04 A˚.
Human AQP4 has also been successfully been crystallized
after 2 years of work and a 1.8 A˚ dataset has been
obtained. This diffraction data permitted the determination
of the structure to a new higher level of resolution than
before. All of these successful structure determinations are
in the process of being written up for publication.
Structure determination by Cryo EM (UCDavis—
Stahlberg)
The Stahlberg lab will continue developing the 2D mem-
brane crystallization technology, the STEM imaging
possibilities, and the maximum likelihood software tools.
STEM imaging will advance due to the installation in the
summer 2008 of an aberration-corrected and energy filtered
200 kV FEG STEM/TEM instrument at UC Davis, for
which the Stahlberg lab is designing a new electron detector
system and protocol to optimally harvest the phase contrast
signal from that instrument. The Stahlberg lab is also
hosting the next international workshop on electron crys-
tallography of membrane proteins at UC Davis, which will
take place Sept. 7–13, 2008 (http://2dx.org/workshop/2008).
The Stahlberg lab continues structural investigations of a
number of membrane protein systems by lipid membrane
reconstitution, 2D crystallization and electron microscopy
imaging trials. We have successfully reconstituted cell-free
expressed CCR5 (from the Choe lab) and see first signs of
structure formation within the membranes. UhpB (Choe) is
reconstituted and forms first small 2D crystals. Reconstitu-
tion was successful, but so far no crystals were obtained
for the sensor protein PhoQ (Choe), the lactate permease
LctP (Kaback), and ABC-R (from the lab of Krys
Palczewski). The Stahlberg lab also has obtained 2D crystals
of a KcsA-MloK1 chimera protein, in collaboration with
Crina Nimigean, NY. These crystals might reveal the KcsA
gating mechanism, since the MloK1 cyclic nucleotide bind-
ing domains can activate or block the KcsA channel function.
2D crystals of the membrane embedded KscA-MloK1
chimera are obtained at different pH values, and structural
analysis is ongoing. We are streamlining the process of
membrane protein structure determination by electron crys-
tallography of 2D crystals.
2D Crystal trial volume reduction
Current 2D crystallization trials are done by dialyzing a
protein-detergent-lipid mixture of a volume of *100 ll
against detergent-free buffer. The Stahlberg lab has devel-
oped devices and a protocol for dialyzing much smaller 5 ll
volumes. First results show that 2D crystallization does not
scale linearly. Crystallization conditions for small and large
volumes are different, and better crystals are generally
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obtained with larger volumes. Nevertheless, the smaller
volumes allow screening a larger number of conditions with
available protein material, after which the best conditions
can be refined with larger volumes.
STEM imaging
Cryo-EM imaging of frozen hydrated and tilted specimen
in the electron microscope suffers from beam-induced
specimen movement or specimen charging, both of which
severely limit the resolution of the structure in the direction
perpendicular to the membrane plane. The Stahlberg group
has compiled data that show that Scanning Transmission
Electron Microscopy (STEM) is not affected by this
problem, thereby bypassing the major bottleneck of elec-
tron crystallography. However, STEM imaging exposes the
samples to very high dose rates of electron beam irradia-
tion, and STEM imaging conventionally does not give
phase contrast images, so that the resulting images have
little contrast at lethal electron doses for the proteins. The
Stahlberg lab now has developed an aberration-corrected
STEM imaging protocol that allows to operate the instru-
ment at membrane-protein compatible electron doses (5
electrons per square angstrom), and also allows access to
the phase contrast signal of the electron-beam/sample
interaction. The Stahlberg lab also has obtained proof of a
strong phase contrast signal under the developed condi-
tions. While it is not yet clear if the phase contrast signal is
comparable to the phase contrast signal in conventional
bright-field cryo-EM imaging, this development neverthe-
less appears likely to allow membrane protein structure
analysis by cryo-EM, without the limitation from beam-
induced specimen movement or charging.
Image processing
The Stahlberg lab continues developing new algorithms for
membrane protein structure reconstruction from cryo-EM
images of badly ordered 2D crystals. Realizing that the
majority of the 2D crystals are not perfectly ordered, or that
quasi-native membrane environments provide no crystallinity
at all, such image processing will enable structure determi-
nation also from reconstituted but not crystalline membrane
proteins. The Stahlberg lab is developing a single-particle 3D
maximum likelihood software solution for such images,
which is integrated into the user friendly 2dx software pack-
age that the Stahlberg lab is distributing (http://2dx.org).
Structure determination of integral membrane proteins
by NMR (Salk, Riek)—small bacterial targets
Based on our structural investigations with MISTIC, we
aim to determine several 3D structures of small integral
membrane proteins of E. coli. E. coli has at least 52 integral
membrane proteins with size smaller than 150 amino acids.
Cloning and expression of all of these proteins have been
initiated using MISTIC-technology in collaboration with S.
Choe.
In parallel, cloning and expression of them without
MISTIC has been established in collaboration with R.
Stroud. In an initial screening, four of these proteins have
been selected for expression and purification. Two of them
(YidH and YgaP) were expressed at 10 mg/l level, were
purified by Ni IMAC and show a dimeric size based on SDS-
gels and size exclusion chromatography. Extensive deter-
gent screening was applied to both proteins. For YidH a good
quality TROSY NMR spectrum was obtained and sequential
assignment is in progress. For this purpose TROSY-based
HNCA, HNCACB and NOESY experiments were recorded.
The TROSY NMR spectrum of YgaP is not yet of good
quality and further detergent screening is initiated.
3D structure determination of corticotropin releasing
factor receptor, a GPCR of family B: We aim to determine
the 3D structure of corticotropin releasing factor receptor
(CRF-R), a G-protein coupled receptor of family B1, by
solution NMR.
In collaboration with the Choe lab we initiated the in
vitro expression of the five somatostatin receptors sst1-sst5,
which belong to the family A GPCRs. The yield for ss2 and
sst5 is about 1 mg/ml reaction mixture. Binding studies
with its ligand somatostatin are positive and indicate that
both receptors are well folded. A 13C, 15N-labeled
somatostatin was synthesized in collaboration with the
Rivier group (The Salk Institute) and the complex forma-
tion between sst2 and 13C, 15N-labeled somatostatin is
initiated to determine the 3D structure of the ligand in
complex with its receptor.
Structural studies on KcsA potassium channel: The core
of the KcsA potassium channel in its closed conformation
has been determined by the MacKinnon group. We studied
in detail the secondary structure as well as the dynamics of
KcsA between open and closed state. It is our finding that
conformational exchange dynamics between locally open
and closed configurations in the filter as well as at the C-
terminal end of transmembrane helix 2 are governing
channel gating elucidating the mechanism of channel
conductance and gating [5]. To our knowledge, this is the
first study to correlate dynamics with function of a mem-
brane protein. In addition, novel techniques are developed
to study the structures and dynamics of membrane proteins.
Summary of all structures determined
The CSMP provided support during the resolution exten-
sion phase of the membrane protein Aquaporin M from
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Methanococcus marbergensis during Year 1, and supported
the X-ray structure of the AmtB/GlnK complex (2NS1)
during Year 2. The CcmG structure has been determined. It
shows the ecto domain that reduces cytochromes clearly,
but the transmembrane domain remains poorly determined.
Refinement should define the domain A structure of Nitr-
osomonas europaea Rh50 has also been determined to a
resolution of 1.99 A˚ in the Stroud laboratory. In addition,
we determined the structure of AcrB—an already deter-
mined structure since it was purified in its endogenous
form on the Ni column due to presence of two histidines.
This is a case where we determined the entire structure, in
two hours after data collection, albeit only to realize that it
was already determined. It was the minor contaminant of
the preparation of another membrane protein of similar
size! Human AQP4 is being refined currently; the dataset is
of high quality, defracting to *1.80 A˚. The Stahlberg
laboratory obtained a 16 A˚ structure of the bacterial
membrane protein MloK1 and the structure has been
deposited at the EMBD Electron Microscopy Database
(5548). The Minor laboratory obtained a 2.07 A˚ structure
or the human membrane protein Kv7.4 (2OVC). The
Kaback laboratory has continued to elucidate the various
conditional structures of lactose permease, determining the
wild type and the acidic and neutral forms (2V8 N/3.60,
2CFP/3.30, and 2CFQ/3.60, respectively.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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